This blog will deal with the social, economic and public policy implications of contemporary science and technology with an emphasis on biomedical aspects.
Friday, February 22, 2013
Thursday, February 14, 2013
Making academic research pay off- is that really the point?
An interesting commentary in
Science by D. Malakoff describes the
many approaches that universities are taking to assure that their research
‘pays off’ in the commercial arena. However, as the article points out, for
every major success, such as NYU’s $650M from Remicade, there are many more
failures with less than 1% of academic intellectual property earning $1M. Many
technology transfer offices cost far more to run than any revenues they return
to the university. To this observer this intense pursuit of commercial and
entrepreneurial activity is another sign of the increasing corporatization of
American universities and a turning away from their traditional role as the
creators of new knowledge that broadly benefits society.
Many research-intensive
universities, especially public ones, are struggling to demonstrate their
economic relevance to their masters in state legislatures. However, trying to
do this on the basis of patents issued or royalties generated is likely to be a
losing proposition. Universities need to devise better appraisals of the positive
impact of their research on economic wellbeing and not have it defined in
narrow commercial terms.
Friday, February 8, 2013
Who needs PhDs?
Now here is a website that
should chill the marrow of all those grad students working hard on their PhDs. Innocentive
is an online company that proposes to solve problems by crowd sourcing. This
apparently includes complex scientific problems involved in drug discovery and
development since the company includes Eli Lilly among its clients. Here is how
it works. Clients (Seekers) can post ‘challenges’ via Innocentive. People
(Solvers) can then respond to the challenge with their ideas. If a successful
solution is provided the Solver gets a prize- whoopee!
Seemingly the client
companies involved seem to think that instead of long term hiring of expensive
scientific staff, they can cherry pick new technologies by offering booby
prizes of a few hundred or a few thousand dollars. So who needs PhDs- maybe Joe
the Plumber can come up with your next research breakthrough!
Outsourcing of research to
China and India is bad enough, but this is worse. In this race to the bottom
the desire to minimize costs is eviscerating the scientific and technological
capabilities of the American pharmaceutical industry. By not investing in
research Big Pharma is on the path of slow motion suicide.
Friday, February 1, 2013
Long term federal funding and career development for young scientists.
An interesting article in
C&EN News discusses attempts to secure multi-year funding for science as
opposed to the current system of annual congressional appropriations. This has
been a dream of many scientists for years, and such stability would no doubt enhance
scientific productivity in the US. The President’s Council of Advisors on
Science & Technology (PCAST) has now come out strongly in favor of the
multi-year approach, but whether this will influence Congress to relax its hold
on the purse strings is in doubt. One aspect of this that isn’t much discussed
is the potential impact on the careers of young scientists. One of the most
difficult aspects of career development in research institutions is the
enormous uncertainty about grant funding. When NIH or NSF funding levels wobble
a few percentage points from year to year it can be a career breaker for early
stage scientists. While multi-year funding wont reduce the intense competition
for grants, at least it would make the process more predictable and allow
better career planning.
Finally- an antisense drug makes it into the clinic!
Congratulations to the ISIS team for getting the first oligonucleotide drug into the clinic. It has been a long time coming, but maybe mipomersen will open the door to other molecules based on antisense, siRNA, or splice switching oligos. Kynamro (mipomersen) is an antisense that targets the RNA for apolipoprotein B100, a component of low density lipoprotein. A small cohort of people with homozygous familial hypercholesterolemia are resistant to statins and have highly elevated cholesterol levels that lead to serious cardiovascular problems at an early age. Kynamro should be able to help these individuals.
http://blogs.nature.com/news/2013/01/fda-approves-antisense-cholesterol-drug.html
http://blogs.nature.com/news/2013/01/fda-approves-antisense-cholesterol-drug.html
Subscribe to:
Posts (Atom)